Heart failure drug showdown: which one saves more lives?
NCT ID NCT07376265
First seen Feb 01, 2026 · Last updated May 09, 2026 · Updated 15 times
Summary
This study looked at health records of over 1,200 people with heart failure to compare two types of medication: sacubitril/valsartan versus ACE inhibitors or ARBs. The goal was to see which treatment better reduced the risk of death from heart problems or hospitalization due to heart failure. Researchers found that sacubitril/valsartan was more effective at preventing these serious events.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis
East Hanover, New Jersey, 07936, United States
Conditions
Explore the condition pages connected to this study.